27.04.2017 • NewsElaine BurridgeOpdivoNSCLC

Bristol-Myers Squibb and Transgene Test Cancer Drug

(c) Science Photo Library RF/Getty Images
(c) Science Photo Library RF/Getty Images

Bristol-Myers Squibb has announced another collaboration to use Opdivo in a combination cancer treatment, this time working with French biotech Transgene. The potential new therapy for advanced non-squamous non-small cell lung cancer (NSCLC) would combine Transgene’s investigational vaccine TG4010 with Opdivo, which is designed to alleviate immune suppression.

The collaboration will assess the safety, tolerability and efficacy of the combined therapy, together with standard chemotherapy, as a first-line treatment for patients with advanced NSCLC where tumors have low or undetectable levels of PD-L1. TG4010 is designed to generate an immune response against tumors that express MUC1, such as NSCLC.

Transgene will sponsor the Phase 2 trial, while Bristol-Myers Squibb will provide Opdivo for use in the study. First results are expected in 2018. “Based on the results obtained with TG4010 in a large Phase 2b trial (TIME trial) in combination with chemotherapy, we are hopeful that this triple combination regimen could provide a treatment option for patients with advanced NSCLC,” said Philippe Archinard, Transgene’s chairman and CEO.

Earlier this month, the US pharma announced it was trialling Opdivo in combination with Apexigen’s humanized monoclonal antibody APX005M to treat patients with advanced solid tumors.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.